Visit https://www.peervoice.com/ZTA860 to view the entire programme with slides. After completing “Novel Targets in T2DM: Incretin Co-Agonists to the Rescue?”, participants will be able to: Discuss emerging clinical evidence for incretin therapies for type 2 diabetes (T2DM) and how these data may impact future management strategies; Describe the function of incretin hormones and their role in the pathogenesis of T2DM;Recognise the benefits of incretin therapies beyond glycaemia control in patients with T2DM